{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:15:14Z","timestamp":1773112514082,"version":"3.50.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s11255-012-0296-8","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T07:09:31Z","timestamp":1349075371000},"page":"1273-1287","source":"Crossref","is-referenced-by-count":3,"title":["The lipid story in chronic kidney disease: a long story with a happy end?"],"prefix":"10.1007","volume":"45","author":[{"given":"Agata","family":"Kujawa-Szewieczek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wi\u0119cek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Piecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,2]]},"reference":[{"key":"296_CR1","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154\u20132169","journal-title":"Circulation"},{"key":"296_CR2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296\u20131305","journal-title":"N Engl J Med"},{"key":"296_CR3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/01.HYP.13.5_Suppl.I80","volume":"13","author":"NB Shulman","year":"1989","unstructured":"Shulman NB, Ford CE, Hall WD et al (1989) Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. Hypertension 13:80\u201393","journal-title":"Hypertension"},{"key":"296_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-140-1-200401060-00006","volume":"140","author":"P Muntner","year":"2004","unstructured":"Muntner P, Hamm LL, Kusek JW et al (2004) The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140:9\u201317","journal-title":"Ann Intern Med"},{"key":"296_CR5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267\u20131278","journal-title":"Lancet"},{"key":"296_CR6","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","volume":"110","author":"M Tonelli","year":"2004","unstructured":"Tonelli M, Isles C, Curhan GC et al (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557\u20131563","journal-title":"Circulation"},{"key":"296_CR7","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1681\/ASN.2005070779","volume":"16","author":"M Tonelli","year":"2005","unstructured":"Tonelli M, Keech A, Shepherd J et al (2005) Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16:3748\u20133754","journal-title":"J Am Soc Nephrol"},{"key":"296_CR8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149\u20131158","journal-title":"Lancet"},{"key":"296_CR9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group (2002) MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7\u201322","journal-title":"Lancet"},{"key":"296_CR10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/ki.2010.524","volume":"79","author":"K Szummer","year":"2011","unstructured":"Szummer K, Lundman P, Jacobson SH et al (2011) Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 79:997\u20131004","journal-title":"Kidney Int"},{"key":"296_CR11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2009.09.020","volume":"55","author":"J Kendrick","year":"2010","unstructured":"Kendrick J, Shlipak MG, Targher G et al (2010) Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force\/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 55:42\u201349","journal-title":"Am J Kidney Dis"},{"key":"296_CR12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","volume":"54","author":"HM Colhoun","year":"2009","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN et al (2009) Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 54:810\u2013819","journal-title":"Am J Kidney Dis"},{"key":"296_CR13","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","volume":"55","author":"PM Ridker","year":"2010","unstructured":"Ridker PM, MacFadyen J, Cressman M et al (2010) Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the use of statins in prevention-an intervention trial evaluating rosuvastatin) trial. J Am Coll Cardiol 55:1266\u20131273","journal-title":"J Am Coll Cardiol"},{"key":"296_CR14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2006.06.003","volume":"117","author":"H Holdaas","year":"2007","unstructured":"Holdaas H, Wanner C, Abletshauser C et al (2007) The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 117:64\u201374","journal-title":"Int J Cardiol"},{"key":"296_CR15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670\u20131681","journal-title":"Lancet"},{"key":"296_CR16","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","volume":"5","author":"H Holdaas","year":"2005","unstructured":"Holdaas H, Fellstr\u00f6m B, Cole E et al (2005) Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 5:2929\u20132936","journal-title":"Am J Transplant"},{"key":"296_CR17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/ndt\/gfh735","volume":"20","author":"H Holdaas","year":"2005","unstructured":"Holdaas H, Fellstr\u00f6m B, Jardine AG et al (2005) Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20:974\u2013980","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR18","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1681\/ASN.2008010101","volume":"19","author":"F Wiesbauer","year":"2008","unstructured":"Wiesbauer F, Heinze G, Mitterbauer C et al (2008) Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol 19:2211\u20132218","journal-title":"J Am Soc Nephrol"},{"key":"296_CR19","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377:2181\u20132192","journal-title":"Lancet"},{"key":"296_CR20","first-page":"26","volume":"17","author":"EBPG Expert Group on Renal Transplantation","year":"2002","unstructured":"EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrol Dial Transplant 17:26\u201328","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)70048-1","volume":"41","author":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) Group","year":"2003","unstructured":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) Group (2003) K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41:1\u201391","journal-title":"Am J Kidney Dis"},{"key":"296_CR22","first-page":"635","volume":"21","author":"M Chmielewski","year":"2008","unstructured":"Chmielewski M, Carrero JJ, Nordfors L et al (2008) Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 21:635\u2013644","journal-title":"J Nephrol"},{"key":"296_CR23","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1093\/ndt\/13.11.2833","volume":"13","author":"PO Attman","year":"1998","unstructured":"Attman PO, Knight-Gibson C, Tavella M et al (1998) The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13:2833\u20132841","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR24","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1046\/j.1523-1755.2003.00019.x","volume":"63","author":"T Hirano","year":"2003","unstructured":"Hirano T, Sakaue T, Misaki A et al (2003) Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 63:2171\u20132177","journal-title":"Kidney Int"},{"key":"296_CR25","first-page":"90","volume":"62","author":"Y Nishizawa","year":"1997","unstructured":"Nishizawa Y, Shoji T, Kawagishi T et al (1997) Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 62:90\u201392","journal-title":"Kidney Int Suppl"},{"key":"296_CR26","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/ndt\/10.12.2381","volume":"10","author":"M Arnadottir","year":"1995","unstructured":"Arnadottir M, Nilsson-Ehle P (1995) Has parathyroid hormone any influence on lipid metabolism in chronic renal failure? Nephrol Dial Transplant 10:2381\u20132382","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR27","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ki.1997.129","volume":"51","author":"ND Vaziri","year":"1997","unstructured":"Vaziri ND, Liang K (1997) Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 51:913\u2013919","journal-title":"Kidney Int"},{"key":"296_CR28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1523-1755.2005.00166.x","volume":"67","author":"C Kim","year":"2005","unstructured":"Kim C, Vaziri ND (2005) Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 67:1028\u20131032","journal-title":"Kidney Int"},{"key":"296_CR29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00041552-200205000-00004","volume":"11","author":"P Heeringa","year":"2002","unstructured":"Heeringa P, Tervaert JW (2002) Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens 11:287\u2013293","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"296_CR30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000079923","volume":"98","author":"J Kasahara","year":"2004","unstructured":"Kasahara J, Kobayashi K, Maeshima Y et al (2004) Clinical significance of serum oxidized low-density lipoprotein\/beta2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract 98:15\u201324","journal-title":"Nephron Clin Pract"},{"key":"296_CR31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0272-6386(00)70255-1","volume":"35","author":"CJ Deighan","year":"2000","unstructured":"Deighan CJ, Caslake MJ, McConnell M et al (2000) Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35:852\u2013862","journal-title":"Am J Kidney Dis"},{"key":"296_CR32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0272-6386(96)90034-7","volume":"27","author":"D O\u2019Neal","year":"1996","unstructured":"O\u2019Neal D, Lee P, Murphy B et al (1996) Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 27:84\u201391","journal-title":"Am J Kidney Dis"},{"key":"296_CR33","first-page":"26","volume":"8","author":"GF Guarnieri","year":"1978","unstructured":"Guarnieri GF, Moracchiello M, Campanacci L et al (1978) Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 8:26\u201330","journal-title":"Kidney Int Suppl"},{"key":"296_CR34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/ki.1984.74","volume":"25","author":"R McLeod","year":"1984","unstructured":"McLeod R, Reeve CE, Frohlich J (1984) Plasma lipoproteins and lecithin:cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 25:683\u2013688","journal-title":"Kidney Int"},{"key":"296_CR35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1152\/ajprenal.00099.2005","volume":"290","author":"ND Vaziri","year":"2006","unstructured":"Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:262\u2013272","journal-title":"Am J Physiol Renal Physiol"},{"key":"296_CR36","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/ndt\/14.6.1462","volume":"14","author":"ND Vaziri","year":"1999","unstructured":"Vaziri ND, Deng G, Liang K (1999) Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplantc 14:1462\u20131466","journal-title":"Nephrol Dial Transplantc"},{"key":"296_CR37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJM199008303230905","volume":"323","author":"J Joven","year":"1990","unstructured":"Joven J, Villabona C, Vilella E et al (1990) Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579\u2013584","journal-title":"N Engl J Med"},{"key":"296_CR38","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1046\/j.1523-1755.2003.00911.x","volume":"63","author":"ND Vaziri","year":"2003","unstructured":"Vaziri ND, Sato T, Liang K (2003) Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 63:1756\u20131763","journal-title":"Kidney Int"},{"key":"296_CR39","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1046\/j.1523-1755.2003.00941.x","volume":"63","author":"ND Vaziri","year":"2003","unstructured":"Vaziri ND (2003) Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63:1964\u20131976","journal-title":"Kidney Int"},{"key":"296_CR40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0021-9150(80)90025-8","volume":"35","author":"ML Kashyap","year":"1980","unstructured":"Kashyap ML, Srivastava LS, Hynd BA et al (1980) Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35:29\u201340","journal-title":"Atherosclerosis"},{"key":"296_CR41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1523-1755.2004.00724.x","volume":"66","author":"ND Vaziri","year":"2004","unstructured":"Vaziri ND, Kim CH, Phan D et al (2004) Up-regulation of hepatic Acyl CoA: diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int 66:262\u2013267","journal-title":"Kidney Int"},{"key":"296_CR42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0009-8981(81)90034-6","volume":"117","author":"T Ohta","year":"1981","unstructured":"Ohta T, Matsuda I (1981) Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clin Chim Acta 117:133\u2013143","journal-title":"Clin Chim Acta"},{"key":"296_CR43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5694\/j.1326-5377.1974.tb93641.x","volume":"2","author":"JH Alexander","year":"1974","unstructured":"Alexander JH, Schapel GJ, Edwards KD (1974) Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust 2:119\u2013122","journal-title":"Med J Aust"},{"key":"296_CR44","first-page":"149","volume":"2","author":"J Joven","year":"1987","unstructured":"Joven J, Rubi\u00e9s-Prat J, Espinel E et al (1987) High-density lipoproteins in untreated idiopathic nephrotic syndrome without renal failure. Nephrol Dial Transplant 2:149\u2013153","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0272-6386(12)70318-9","volume":"22","author":"AK Cheung","year":"1993","unstructured":"Cheung AK, Wu LL, Kablitz C et al (1993) Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22:271\u2013276","journal-title":"Am J Kidney Dis"},{"key":"296_CR46","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJM197812142992402","volume":"299","author":"J Rapoport","year":"1978","unstructured":"Rapoport J, Aviram M, Chaimovitz C et al (1978) Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med 299:1326\u20131329","journal-title":"N Engl J Med"},{"key":"296_CR47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000186303","volume":"57","author":"PO Attman","year":"1991","unstructured":"Attman PO, Alaupovic P (1991) Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 57:401\u2013410","journal-title":"Nephron"},{"key":"296_CR48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2369-5-17","volume":"5","author":"B N\u00e4sstr\u00f6m","year":"2004","unstructured":"N\u00e4sstr\u00f6m B, Stegmayr B, Olivecrona G et al (2004) Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. BMC Nephrol 5:17","journal-title":"BMC Nephrol"},{"key":"296_CR49","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1681\/ASN.V591703","volume":"5","author":"PJ Blankestijn","year":"1995","unstructured":"Blankestijn PJ, Vos PF, Rabelink TJ et al (1995) High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 5:1703\u20131708","journal-title":"J Am Soc Nephrol"},{"key":"296_CR50","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1046\/j.1523-1755.1999.00375.x","volume":"55","author":"PO Attman","year":"1999","unstructured":"Attman PO, Samuelsson OG, Moberly J et al (1999) Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 55:1536\u20131542","journal-title":"Kidney Int"},{"key":"296_CR51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1523-1755.63.s84.23.x","volume":"84","author":"F Kronenberg","year":"2003","unstructured":"Kronenberg F, Lingenhel A, Neyer U et al (2003) Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 84:113\u2013116","journal-title":"Kidney Int Suppl"},{"key":"296_CR52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","volume":"6","author":"F Kronenberg","year":"1995","unstructured":"Kronenberg F, K\u00f6nig P, Neyer U et al (1995) Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110\u2013120","journal-title":"J Am Soc Nephrol"},{"key":"296_CR53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/089686080002000307","volume":"20","author":"AC Johansson","year":"2000","unstructured":"Johansson AC, Samuelsson O, Attman PO et al (2000) Dyslipidemia in peritoneal dialysis\u2013relation to dialytic variables. Perit Dial Int 20:306\u2013314","journal-title":"Perit Dial Int"},{"key":"296_CR54","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1523-1755.2004.00466.x","volume":"65","author":"BH Prinsen","year":"2004","unstructured":"Prinsen BH, Rabelink TJ, Romijn JA et al (2004) A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int 65:1064\u20131075","journal-title":"Kidney Int"},{"key":"296_CR55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0021-9150(89)90032-4","volume":"79","author":"J Steele","year":"1989","unstructured":"Steele J, Billington T, Janus E et al (1989) Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Atherosclerosis 79:47\u201350","journal-title":"Atherosclerosis"},{"key":"296_CR56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","volume":"32","author":"RN Foley","year":"1998","unstructured":"Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:112\u2013119","journal-title":"Am J Kidney Dis"},{"key":"296_CR57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5414\/CNP57327","volume":"5","author":"MJ Sarnak","year":"2002","unstructured":"Sarnak MJ, Coronado BE, Greene T et al (2002) Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 5:327\u2013335","journal-title":"Clin Nephrol"},{"key":"296_CR58","first-page":"24","volume":"9","author":"J Coresh","year":"1998","unstructured":"Coresh J, Longenecker JC, Miller ER III et al (1998) Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:24\u201330","journal-title":"J Am Soc Nephrol"},{"key":"296_CR59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","volume":"11","author":"F Kronenberg","year":"2000","unstructured":"Kronenberg F, Kuen E, Ritz E et al (2000) Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11:105\u2013115","journal-title":"J Am Soc Nephrol"},{"key":"296_CR60","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","volume":"10","author":"F Kronenberg","year":"1999","unstructured":"Kronenberg F, Neyer U, Lhotta K et al (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10:1027\u20131036","journal-title":"J Am Soc Nephrol"},{"key":"296_CR61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0140-6736(69)90110-X","volume":"2","author":"GM Berlyne","year":"1969","unstructured":"Berlyne GM, Mallick NP (1969) Ischaemic heart-disease as a complication of nephrotic syndrome. Lancet 2:399\u2013400","journal-title":"Lancet"},{"key":"296_CR62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000182025","volume":"27","author":"V Wass","year":"1981","unstructured":"Wass V, Cameron JS (1981) Cardiovascular disease and the nephrotic syndrome: the other side of the coin. Nephron 27:58\u201361","journal-title":"Nephron"},{"key":"296_CR63","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","volume":"44","author":"JD Ordo\u00f1ez","year":"1993","unstructured":"Ordo\u00f1ez JD, Hiatt RA, Killebrew EJ et al (1993) The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638\u2013642","journal-title":"Kidney Int"},{"key":"296_CR64","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00467-004-1460-x","volume":"19","author":"BL Lechner","year":"2004","unstructured":"Lechner BL, Bockenhauer D, Iragorri S et al (2004) The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol 19:744\u2013748","journal-title":"Pediatr Nephrol"},{"key":"296_CR65","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1523-1755.2000.00173.x","volume":"58","author":"AK Cheung","year":"2000","unstructured":"Cheung AK, Sarnak MJ, Yan G et al (2000) Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353\u2013362","journal-title":"Kidney Int"},{"key":"296_CR66","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.CIR.86.2.475","volume":"86","author":"MD Cressman","year":"1992","unstructured":"Cressman MD, Heyka RJ, Paganini EP et al (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475\u2013482","journal-title":"Circulation"},{"key":"296_CR67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0021-9150(83)90045-X","volume":"48","author":"R Hahn","year":"1983","unstructured":"Hahn R, Oette K, Mondorf H et al (1983) Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48:279\u2013288","journal-title":"Atherosclerosis"},{"key":"296_CR68","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1046\/j.1523-1755.2002.00324.x","volume":"61","author":"K Iseki","year":"2002","unstructured":"Iseki K, Yamazato M, Tozawa M et al (2002) Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61:1887\u20131893","journal-title":"Kidney Int"},{"key":"296_CR69","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1053\/ajkd.2001.29222","volume":"38","author":"K Kalantar-Zadeh","year":"2001","unstructured":"Kalantar-Zadeh K, Kopple JD, Block G et al (2001) A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 38:1251\u20131263","journal-title":"Am J Kidney Dis"},{"key":"296_CR70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2006070795","volume":"18","author":"RD Kilpatrick","year":"2007","unstructured":"Kilpatrick RD, McAllister CJ, Kovesdy CP et al (2007) Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18:293\u2013303","journal-title":"J Am Soc Nephrol"},{"key":"296_CR71","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","volume":"15","author":"EG Lowrie","year":"1990","unstructured":"Lowrie EG, Lew NL (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458\u2013482","journal-title":"Am J Kidney Dis"},{"key":"296_CR72","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","volume":"291","author":"Y Liu","year":"2004","unstructured":"Liu Y, Coresh J, Eustace JA et al (2004) Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291:451\u2013459","journal-title":"JAMA"},{"key":"296_CR73","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1523-1755.1999.07167.x","volume":"71","author":"Y Koda","year":"1999","unstructured":"Koda Y, Nishi S, Suzuki M et al (1999) Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 71:251\u2013253","journal-title":"Kidney Int Suppl"},{"key":"296_CR74","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/089686089301302S102","volume":"13","author":"AT Webb","year":"1993","unstructured":"Webb AT, Brown EA (1993) Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13:406\u2013408","journal-title":"Perit Dial Int"},{"key":"296_CR75","first-page":"373","volume":"8","author":"J Olivares","year":"1992","unstructured":"Olivares J, Cruz C, Gas JM et al (1992) Evolution of lipid profiles in long-term peritoneal dialysis. Adv Perit Dial 8:373\u2013375","journal-title":"Adv Perit Dial"},{"key":"296_CR76","first-page":"513","volume":"37","author":"MH Gault","year":"1991","unstructured":"Gault MH, Longerich L, Prabhakaran V et al (1991) Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD. ASAIO Trans 37:513\u2013514","journal-title":"ASAIO Trans"},{"key":"296_CR77","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ndt\/10.supp6.72","volume":"10","author":"GB Piccoli","year":"1995","unstructured":"Piccoli GB, Quarello F, Salomone M et al (1995) Are serum albumin and cholesterol reliable outcome markers in elderly dialysis patients? Nephrol Dial Transplant 10:72\u201377","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR78","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0272-6386(96)90398-4","volume":"28","author":"R Sreedhara","year":"1996","unstructured":"Sreedhara R, Avram MM, Blanco M et al (1996) Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis 28:937\u2013942","journal-title":"Am J Kidney Dis"},{"key":"296_CR79","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/089686080202200408","volume":"22","author":"EA Iliescu","year":"2002","unstructured":"Iliescu EA, Marcovina SM, Morton AR et al (2002) Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int 22:492\u2013499","journal-title":"Perit Dial Int"},{"key":"296_CR80","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"2","author":"JF Moorhead","year":"1982","unstructured":"Moorhead JF, Chan MK, El-Nahas M et al (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309\u20131311","journal-title":"Lancet"},{"key":"296_CR81","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1523-1755.1999.07116.x","volume":"71","author":"J Galle","year":"1999","unstructured":"Galle J, Heermeier K, Wanner C (1999) Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl 71:62\u201365","journal-title":"Kidney Int Suppl"},{"key":"296_CR82","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1681\/ASN.2004080629","volume":"16","author":"B Bussolati","year":"2005","unstructured":"Bussolati B, Deregibus MC, Fonsato V et al (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase\/AKT-signaling pathway. J Am Soc Nephrol 16:1936\u20131947","journal-title":"J Am Soc Nephrol"},{"key":"296_CR83","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11906-012-0250-2","volume":"14","author":"L Gyebi","year":"2012","unstructured":"Gyebi L, Soltani Z, Reisin E (2012) Lipid Nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 14:177\u2013181","journal-title":"Curr Hypertens Rep"},{"key":"296_CR84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1523-1755.1999.07104.x","volume":"71","author":"PO Attman","year":"1999","unstructured":"Attman PO, Alaupovic P, Samuelsson O (1999) Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int Suppl 71:14\u201317","journal-title":"Kidney Int Suppl"},{"key":"296_CR85","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","volume":"110","author":"FW Asselbergs","year":"2004","unstructured":"Asselbergs FW, Diercks GF, Hillege HL et al (2004) Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110:2809\u20132816","journal-title":"Circulation"},{"key":"296_CR86","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ahj.2011.03.028","volume":"161","author":"FP Brouwers","year":"2011","unstructured":"Brouwers FP, Asselbergs FW, Hillege HL et al (2011) Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 161:1171\u20131178","journal-title":"Am Heart J"},{"key":"296_CR87","first-page":"7784","volume":"2","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Pansini F, Perkovic V et al (2009) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2:7784","journal-title":"Cochrane Database Syst Rev"},{"key":"296_CR88","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","volume":"361","author":"H Holdaas","year":"2003","unstructured":"Holdaas H, Fellstr\u00f6m B, Jardine AG et al (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361:2024\u20132031","journal-title":"Lancet"},{"key":"296_CR89","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","volume":"66","author":"M Tonelli","year":"2004","unstructured":"Tonelli M, Collins D, Robins S et al (2004) Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66:1123\u20131130","journal-title":"Kidney Int"},{"key":"296_CR90","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/ndt\/gfn528","volume":"24","author":"FC Cormack-Aboud","year":"2009","unstructured":"Cormack-Aboud FC, Brinkkoetter PT, Pippin JW et al (2009) Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 24:404\u2013412","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR91","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1093\/ndt\/gfp012","volume":"24","author":"N Sakurai","year":"2009","unstructured":"Sakurai N, Kuroiwa T, Ikeuchi H et al (2009) Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol Dial Transplant 24:2378\u20132383","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR92","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","volume":"57","author":"VG Athyros","year":"2004","unstructured":"Athyros VG, Mikhailidis DP, Papageorgiou AA et al (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:728\u2013734","journal-title":"J Clin Pathol"},{"key":"296_CR93","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","volume":"2","author":"J Shepherd","year":"2007","unstructured":"Shepherd J, Kastelein JJ, Bittner V et al (2007) Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2:1131\u20131139","journal-title":"Clin J Am Soc Nephrol"},{"key":"296_CR94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.104.517565","volume":"112","author":"M Tonelli","year":"2005","unstructured":"Tonelli M, Isles C, Craven T et al (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171\u2013178","journal-title":"Circulation"},{"key":"296_CR95","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","volume":"17","author":"S Sandhu","year":"2006","unstructured":"Sandhu S, Wiebe N, Fried LF et al (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006\u20132016","journal-title":"J Am Soc Nephrol"},{"key":"296_CR96","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1507\/endocrj.K11E-080","volume":"58","author":"M Abe","year":"2011","unstructured":"Abe M, Maruyama N, Yoshida Y et al (2011) Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocr J 58:663\u2013674","journal-title":"Endocr J"},{"key":"296_CR97","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","volume":"41","author":"S Bianchi","year":"2003","unstructured":"Bianchi S, Bigazzi R, Caiazza A et al (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565\u2013570","journal-title":"Am J Kidney Dis"},{"key":"296_CR98","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1523-1755.2002.00109.x","volume":"61","author":"SL Seliger","year":"2002","unstructured":"Seliger SL, Weiss NS, Gillen DL et al (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297\u2013304","journal-title":"Kidney Int"},{"key":"296_CR99","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2004.09.025","volume":"45","author":"NA Mason","year":"2005","unstructured":"Mason NA, Bailie GR, Satayathum S et al (2005) HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119\u2013126","journal-title":"Am J Kidney Dis"},{"key":"296_CR100","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1093\/ndt\/gfr229","volume":"26","author":"JE Lee","year":"2011","unstructured":"Lee JE, Oh KH, Choi KH et al (2011) Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison. Nephrol Dial Transplant 26:4090\u20134094","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR101","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238\u2013248","journal-title":"N Engl J Med"},{"key":"296_CR102","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395\u20131407","journal-title":"N Engl J Med"},{"key":"296_CR103","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.2010090987","volume":"22","author":"H Holdaas","year":"2011","unstructured":"Holdaas H, Holme I, Schmieder RE et al (2011) Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 22:1335\u20131341","journal-title":"J Am Soc Nephrol"},{"key":"296_CR104","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/ndt\/15.4.454","volume":"15","author":"C Zoccali","year":"2000","unstructured":"Zoccali C (2000) Cardiovascular risk in uraemic patients\u2014is it fully explained by classical risk factors? Nephrol Dial Transplant 15:454\u2013457","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5414\/CNP60013","volume":"60","author":"K Amann","year":"2003","unstructured":"Amann K, Tyralla K, Gross ML et al (2003) Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 60:13\u201321","journal-title":"Clin Nephrol"},{"key":"296_CR106","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","volume":"18","author":"GM London","year":"2003","unstructured":"London GM, Gu\u00e9rin AP, Marchais SJ et al (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731\u20131740","journal-title":"Nephrol Dial Transplant"},{"key":"296_CR107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000320370","volume":"30","author":"M Kanbay","year":"2010","unstructured":"Kanbay M, Afsar B, Goldsmith D et al (2010) Sudden death in hemodialysis: an update. Blood Purif 30:135\u2013145","journal-title":"Blood Purif"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-012-0296-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T21:10:28Z","timestamp":1643490628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-012-0296-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,2]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1007\/s11255-012-0296-8","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,2]]}}}